
    
      Docetaxel and gemcitabine are well known active agents in the treatment of NSCLC. The
      standard treatment of elderly patients with advanced NSCLC is monotherapy with a third
      generation agent. However, there are only few randomized trials evaluating a two drug
      combination specifically addressed to elderly patients. The role of comprehensive geriatric
      assessment in treatment efficacy and tolerance is an area of investigation
    
  